Foghorn Therapeutics (FHTX) Plummets 49% as Eli Lilly Terminates Cancer Partnership

Quick Summary

Table of Contents

Shares of Foghorn Therapeutics plummeted 49% to $1.84 following Eli Lilly’s termination of their collaborative cancer drug development agreement.
Both parties chose to discontinue FHD-909 from advancing to expanded clinical testing after underwhelming Phase 1 data.
An additional joint program targeting SMARCA2 degradation has been abandoned as well.
Foghorn plans to reduce its employee headcount by approximately 40% as a cash preservation measure.
Management projects the company’s financial reserves will last through late 2029 following restructuring.

Shares of Foghorn Therapeutics experienced a dramatic collapse Thursday following the biotech’s disclosure that its collaboration with pharmaceutical giant Eli Lilly had been terminated. The stock plunged 49% to $1.84 after trading resumed, representing the company’s steepest single-session decline in its history.

Foghorn Therapeutics Inc., FHTX

Shares were temporarily suspended before the announcement. Once the halt lifted, selling pressure intensified rapidly.

The biotech’s market capitalization now sits around $212 million. This represents a dramatic downturn for a company that previously collaborated with one of the pharmaceutical industry’s largest players.

The partners mutually agreed to discontinue advancement of FHD-909 beyond its recently completed Phase 1 dose escalation study.

FHD-909 was an oral small molecule designed to selectively target the SMARCA2 protein. The therapeutic approach relied on synthetic lethality principles, exploiting specific genetic vulnerabilities present in certain tumor types.

Reasons Behind the Program Termination

Chief Executive Adrian Gottschalk noted that the compound successfully engaged its intended molecular target. The safety profile remained acceptable throughout testing, even when doses exceeded levels initially predicted by preclinical research.

However, clinical efficacy proved insufficient. Gottschalk explained that the underlying scientific rationale involving SMARCA2/4 interactions failed to produce therapeutic responses robust enough to justify continued investment.

This disappointing conclusion arrives after multiple years of collaborative development. The setback extends beyond a single experimental therapy.

Both organizations confirmed that a separate oncology collaboration focused on selective SMARCA2 degradation technology will also be discontinued. Foghorn indicated no additional cooperative initiatives with Lilly are anticipated moving forward.

The original collaboration was established in December 2021. Lilly’s Loxo Oncology division structured the agreement with $300 million in initial payments alongside an $80 million equity investment priced at $20 per share.

Those financial terms appeared favorable for Foghorn when announced. The current trading price stands dramatically below that initial $20 valuation.

Foghorn’s Path Forward

Following the partnership dissolution, Foghorn has implemented aggressive cost reduction strategies. The organization is eliminating nearly 40% of its workforce alongside broader operational restructuring.

Leadership believes these adjustments will extend available capital through the latter half of 2029. This timeline provides runway to sustain development of remaining pipeline candidates.

Foghorn stated it will concentrate resources on wholly-owned proprietary assets. This portfolio encompasses a selective EP300 degrader, a selective CBP degrader, and an oral program targeting immunology and inflammatory conditions.

The organization continues prioritizing its induced proximity technology platform as a foundational capability. These strategic areas operate independently of Lilly’s financial support.

For Eli Lilly, market reaction was minimal. Shares declined roughly 2%, an insignificant movement for a corporation of its scale.

For Foghorn, the implications are far more consequential. The biotech now operates primarily independently, relying on existing capital reserves and a streamlined organization to advance its development programs through the coming years.

✨ Limited Time Offer